Through collaboration Intrexon is working to discover and develop ActoBiotics® therapies
directed against selected targets to treat Type 2 diabetes (T2D), obesity and/or metabolic disorders related to energy dysregulation. Intrexon's ActoBiotics®
platform represents an innovative oral delivery system for biological effectors ideally suited to tackle multiple aspects of T2D with the potential to improve efficacy in maintaining glycemic control in the long term. Diabetes is one of today's most pressing health problems, afflicting more than 387 million people worldwide at a cost exceeding $376 billion.